SkinBioTherapeutics PLC (LON:SBTX) said its SkinBiotix technology was successful in stability-testing.
"Demonstrating the extended stability of the cream formulation was a key step to commencing the human study. This remains on track to start this month," said chief executive, Dr Cath O’Neill.
WATCH: SkinBioTherapeutics achieves 'commercial levels of scale-up' of its technology
The cream uses extracts of probiotic bacteria that have been shown to increase the skin's barrier integrity by enhancing the formation of multi-protein complexes called tight junctions.
Tight junctions seal the space between cells to prevent the passage of toxins, molecules and ions through these spaces.
Human studies
In doing so, it is hoped the cream can protect the body’s largest organ from harmful pathogens and increase its rate of healing.
The company’s first-in-human study of SkinBiotix will be carried out over 30 days to assess skin hydration and barrier function.
In parallel, the formulations will also be assessed to ensure that no inflammation of the skin occurs.
If positive, the data will allow the company to use the term 'dermatologically tested' for its formulations.
The shares rose 15% to 22.34p, valuing the business at £26mln. In the past six months, the stock has more than doubled in value.